Cargando…
B7 family protein glycosylation: Promising novel targets in tumor treatment
Cancer immunotherapy, including the inhibition of immune checkpoints, improves the tumor immune microenvironment and is an effective tool for cancer therapy. More effective and alternative inhibitory targets are critical for successful immune checkpoint blockade therapy. The interaction of the immun...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763287/ https://www.ncbi.nlm.nih.gov/pubmed/36561746 http://dx.doi.org/10.3389/fimmu.2022.1088560 |
_version_ | 1784853023372083200 |
---|---|
author | Xiao, Linlin Guan, Xiaoyan Xiang, Mingli Wang, Qian Long, Qian Yue, Chaoyi Chen, Lulu Liu, Jianguo Liao, Chengcheng |
author_facet | Xiao, Linlin Guan, Xiaoyan Xiang, Mingli Wang, Qian Long, Qian Yue, Chaoyi Chen, Lulu Liu, Jianguo Liao, Chengcheng |
author_sort | Xiao, Linlin |
collection | PubMed |
description | Cancer immunotherapy, including the inhibition of immune checkpoints, improves the tumor immune microenvironment and is an effective tool for cancer therapy. More effective and alternative inhibitory targets are critical for successful immune checkpoint blockade therapy. The interaction of the immunomodulatory ligand B7 family with corresponding receptors induces or inhibits T cell responses by sending co-stimulatory and co-inhibitory signals respectively. Blocking the glycosylation of the B7 family members PD-L1, PD-L2, B7-H3, and B7-H4 inhibited the self-stability and receptor binding of these immune checkpoint proteins, leading to immunosuppression and rapid tumor progression. Therefore, regulation of glycosylation may be the “golden key” to relieve tumor immunosuppression. The exploration of a more precise glycosylation regulation mechanism and glycan structure of B7 family proteins is conducive to the discovery and clinical application of antibodies and small molecule inhibitors. |
format | Online Article Text |
id | pubmed-9763287 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97632872022-12-21 B7 family protein glycosylation: Promising novel targets in tumor treatment Xiao, Linlin Guan, Xiaoyan Xiang, Mingli Wang, Qian Long, Qian Yue, Chaoyi Chen, Lulu Liu, Jianguo Liao, Chengcheng Front Immunol Immunology Cancer immunotherapy, including the inhibition of immune checkpoints, improves the tumor immune microenvironment and is an effective tool for cancer therapy. More effective and alternative inhibitory targets are critical for successful immune checkpoint blockade therapy. The interaction of the immunomodulatory ligand B7 family with corresponding receptors induces or inhibits T cell responses by sending co-stimulatory and co-inhibitory signals respectively. Blocking the glycosylation of the B7 family members PD-L1, PD-L2, B7-H3, and B7-H4 inhibited the self-stability and receptor binding of these immune checkpoint proteins, leading to immunosuppression and rapid tumor progression. Therefore, regulation of glycosylation may be the “golden key” to relieve tumor immunosuppression. The exploration of a more precise glycosylation regulation mechanism and glycan structure of B7 family proteins is conducive to the discovery and clinical application of antibodies and small molecule inhibitors. Frontiers Media S.A. 2022-12-06 /pmc/articles/PMC9763287/ /pubmed/36561746 http://dx.doi.org/10.3389/fimmu.2022.1088560 Text en Copyright © 2022 Xiao, Guan, Xiang, Wang, Long, Yue, Chen, Liu and Liao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Xiao, Linlin Guan, Xiaoyan Xiang, Mingli Wang, Qian Long, Qian Yue, Chaoyi Chen, Lulu Liu, Jianguo Liao, Chengcheng B7 family protein glycosylation: Promising novel targets in tumor treatment |
title | B7 family protein glycosylation: Promising novel targets in tumor treatment |
title_full | B7 family protein glycosylation: Promising novel targets in tumor treatment |
title_fullStr | B7 family protein glycosylation: Promising novel targets in tumor treatment |
title_full_unstemmed | B7 family protein glycosylation: Promising novel targets in tumor treatment |
title_short | B7 family protein glycosylation: Promising novel targets in tumor treatment |
title_sort | b7 family protein glycosylation: promising novel targets in tumor treatment |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763287/ https://www.ncbi.nlm.nih.gov/pubmed/36561746 http://dx.doi.org/10.3389/fimmu.2022.1088560 |
work_keys_str_mv | AT xiaolinlin b7familyproteinglycosylationpromisingnoveltargetsintumortreatment AT guanxiaoyan b7familyproteinglycosylationpromisingnoveltargetsintumortreatment AT xiangmingli b7familyproteinglycosylationpromisingnoveltargetsintumortreatment AT wangqian b7familyproteinglycosylationpromisingnoveltargetsintumortreatment AT longqian b7familyproteinglycosylationpromisingnoveltargetsintumortreatment AT yuechaoyi b7familyproteinglycosylationpromisingnoveltargetsintumortreatment AT chenlulu b7familyproteinglycosylationpromisingnoveltargetsintumortreatment AT liujianguo b7familyproteinglycosylationpromisingnoveltargetsintumortreatment AT liaochengcheng b7familyproteinglycosylationpromisingnoveltargetsintumortreatment |